T.O.3 SNT-MC17/idebenone in Duchenne muscular dystrophy: long-term blinded controlled preclinical study in the mdx mouse followed by a 12 month double-blind randomized controlled trial in humans

2008 ◽  
Vol 18 (9-10) ◽  
pp. 832 ◽  
Author(s):  
G.M. Buyse ◽  
N. Goemans ◽  
G. Van der Mieren ◽  
M. Erb ◽  
J. D’hooge ◽  
...  
2011 ◽  
Vol 7 (5) ◽  
pp. 371-376 ◽  
Author(s):  
Eugenia Oviedo-Joekes, PhD ◽  
David C. Marsh, MD ◽  
Daphne Guh, MSc ◽  
Suzanne Brissette, MD ◽  
Martin T. Schechter, MD, PhD

Background: Data on conversion ratios for switching opioids in substitution treatment are limited.Methods: Data were obtained from a randomized controlled trial among long-term opioid-dependent patients conducted in Vancouver and Montreal, Canada. Patients received diacetylmorphine (n 115) or hydromorphone (n 25) on a double-blind basis, on a 1:3 potency ratio with individually adjusted dosage, both injectable.Results: Average daily dosages of hydromorphone and diacetylmorphine prescribed were 212.6 mg and 454.0 mg, respectively; potency ratio was 1:2.0-2.2 at different dose ranges.Conclusions: Studies using hydromorphone as a diacetylmorphine equivalent should consider the ratio found in this study to achieve equipotency and maintain the blinding.


2018 ◽  
Vol 7 (2) ◽  
pp. 107-115 ◽  
Author(s):  
Thais Massetti ◽  
Francis Meire Fávero ◽  
Lilian Del Ciello de Menezes ◽  
Mayra Priscila Boscolo Alvarez ◽  
Tânia Brusque Crocetta ◽  
...  

2019 ◽  
Vol 10 ◽  
Author(s):  
Bruna Leal de Freitas ◽  
Talita Dias da Silva ◽  
Tânia Brusque Crocetta ◽  
Thais Massetti ◽  
Luciano Vieira de Araújo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document